High pre-therapeutic and 24-h post-treatment values in serum high mobility group box 1 (HMGB1), a nucleoprotein inflammatory cytokine that triggers protective T-cell response and promotes tumor neoangiogenesis, were associated with lower OS [175]. This evidence concerns the gene HMGB1 and neoplasm.